Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01715909
- Locations
- 🇺🇸
Lucile Packard Child Hosp; Pediatric Pulmonary Division, Palo Alto, California, United States
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇷Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
- Conditions
- Cardiovascular Disease, Diabetes Mellitus Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1999
- Registration Number
- NCT01715818
A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT01715831
- Locations
- 🇧🇷
Hospital Universitario Cassiano Antonio Moraes - UFES; Reumatologia, Vitoria, ES, Brazil
🇧🇷Centro Mineiro de Pesquisa - CMIP, Juiz de Fora, MG, Brazil
🇧🇷Universidade Federal de Sao Paulo - UNIFESP; Reumatologia, Sao Paulo, SP, Brazil
A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01714154
An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 351
- Registration Number
- NCT01712347
- Locations
- 🇨🇳
Chang Gung Medical Foundation - Chai Yi; Surgery, Chai Yi, Taiwan
🇨🇳Kaohsiung Chang Gung Memorial Hospital; Colorectal Surgery, Kaohsiung, Taiwan
🇨🇳National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan, Taiwan
A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01711775
A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT01711801
A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01708616
An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients
- Conditions
- Kidney Transplantation
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 414
- Registration Number
- NCT01707550
A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Pegylated Interferon (Peginterferon) Alfa-2aDrug: Nucleos(t)ide Analogues (NA)
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT01706575
- Locations
- 🇮🇹
A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Medica, Udine, Friuli-Venezia Giulia, Italy
🇮🇹Policlinico Umberto I Di Roma, Roma, Lazio, Italy
🇮🇹Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy